Jake Bauer

Mr. Jake Bauer is a Chairman at Bridgebio Oncology Therapeutics, Inc., a Chairman at Bridgebio Oncology Therapeutics, Inc. /New/, an Independent Director at Immunovant, Inc., an Independent Director at Enliven Therapeutics, Inc., an Independent Director at Attralus, Inc., a Venture Partner at ARCH Venture Partners LLC, a Chairman at Simcha Therapeutics, Inc., a Venture Partner at GSK Equity Investments Ltd. and a Venture Partner at SR One Capital Management LP.
He is on the Board of Directors at Immunovant, Inc., Enliven Therapeutics, Inc., Enliven Therapeutics, Inc. /US/, Attralus, Inc. and Simcha Therapeutics Holding Co. LLC.
Mr. Bauer was previously employed as an Independent Director by ARYA Sciences Acquisition Corp.
V, a Consultant by Bristol Myers Squibb Co., an Independent Director by ARYA Sciences Acquisition Corp.
II, a Chief Business Officer by MyoKardia, Inc., a VP-Business Operations & Head-Development by Ablexis LLC, a Principal by Third Rock Ventures LLC, a Management Consultant by Putnam Associates LLC, a Principal by Agios Pharmaceuticals, Inc., a Principal by CytomX LLC, a Principal by Endo Health Solutions, Inc., a Principal by Global Blood Therapeutics, Inc., an Associate by Royalty Pharma Cayman Partners LP, and a Principal by Zafgen, Inc. He also served on the board at Phoenix Tissue Repair, Inc. He received his undergraduate degree from Duke University and an MBA from Harvard Business School.